Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Macrogenics (MGNX) EBT (2016 - 2025)

Historic EBT for Macrogenics (MGNX) over the last 14 years, with Q3 2025 value amounting to $16.8 million.

  • Macrogenics' EBT fell 7012.56% to $16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$76.5 million, marking a year-over-year increase of 2613.72%. This contributed to the annual value of -$66.0 million for FY2024, which is 62888.05% down from last year.
  • Macrogenics' EBT amounted to $16.8 million in Q3 2025, which was down 7012.56% from -$36.1 million recorded in Q2 2025.
  • Over the past 5 years, Macrogenics' EBT peaked at $56.3 million during Q3 2024, and registered a low of -$66.6 million during Q1 2022.
  • For the 5-year period, Macrogenics' EBT averaged around -$32.9 million, with its median value being -$41.8 million (2022).
  • As far as peak fluctuations go, Macrogenics' EBT tumbled by 258368.66% in 2021, and later skyrocketed by 25860.8% in 2024.
  • Over the past 5 years, Macrogenics' EBT (Quarter) stood at -$58.2 million in 2021, then soared by 120.58% to $12.0 million in 2022, then plummeted by 511.87% to -$49.4 million in 2023, then soared by 70.67% to -$14.5 million in 2024, then surged by 216.2% to $16.8 million in 2025.
  • Its EBT was $16.8 million in Q3 2025, compared to -$36.1 million in Q2 2025 and -$42.7 million in Q1 2025.